Hormone weight loss pills — or more accurately, hormone-based weight loss medications — represent a significant advance in the medical management of obesity. These prescription-only treatments work by mimicking gut hormones to reduce appetite and promote fullness, offering a new approach for adults who have not achieved sufficient weight loss through lifestyle changes alone. In the UK, licensed options include GLP-1 receptor agonists such as semaglutide (Wegovy) and liraglutide (Saxenda), as well as the dual agonist tirzepatide (Mounjaro). This article explains how these medicines work, who may be eligible, their risks, and how they fit within NHS and NICE guidance.

What Are Hormone-Based Weight Loss Medications?

Hormone-based weight loss medications are prescription-only medicines — primarily GLP-1 receptor agonists — that mimic gut hormones to reduce appetite and are regulated by the MHRA; they are administered by injection, not as pills.

Hormone-based weight loss medications are a class of prescription medicines that work by mimicking or influencing the action of naturally occurring hormones involved in appetite regulation, metabolism, and blood glucose control. Unlike older weight loss drugs that acted primarily on the central nervous system, this newer generation of treatments targets specific hormonal pathways in the gut and brain to reduce hunger and promote a feeling of fullness.

The most widely recognised of these are the glucagon-like peptide-1 (GLP-1) receptor agonists, which include medicines such as semaglutide (Wegovy, licensed for weight management; Ozempic, licensed for type 2 diabetes) and liraglutide (Saxenda, licensed for weight management). A newer dual agonist, tirzepatide (Mounjaro), is also licensed in the UK for weight management.

Important: All currently licensed GLP-1 and GIP-based weight management treatments in the UK are administered by subcutaneous injection — they are not tablets or capsules. Oral semaglutide (Rybelsus) is licensed for type 2 diabetes only and is not licensed for weight management in the UK. The term 'hormone weight loss pills' is therefore somewhat misleading, and patients should be aware of this distinction.

These medicines are regulated prescription-only medicines, approved by the Medicines and Healthcare products Regulatory Agency (MHRA). Regulatory status and safety information for each medicine is set out in the relevant Summary of Product Characteristics (SmPC), available via the Electronic Medicines Compendium (emc).

The term 'hormone weight loss pills' is sometimes used loosely online to describe a broad range of products, including unregulated supplements. Patients should be cautious: only licensed prescription medicines have been rigorously assessed for safety and efficacy. Any product claiming to alter hormones for weight loss without a prescription should be treated with significant scepticism, and advice sought from a qualified healthcare professional before use.

How These Medications Work in the Body

GLP-1 receptor agonists mimic the gut hormone GLP-1 to suppress appetite via the hypothalamus, slow gastric emptying, and stimulate insulin release; tirzepatide additionally targets GIP receptors for enhanced effect.

GLP-1 receptor agonists work by mimicking the action of glucagon-like peptide-1, a hormone naturally released from the gut after eating. By binding to GLP-1 receptors in the pancreas, brain, and gastrointestinal tract, these medicines produce several coordinated effects that support weight reduction:

• Appetite suppression: They act on the hypothalamus in the brain to reduce hunger signals, helping individuals feel less inclined to eat.

• Slowed gastric emptying: Food moves more slowly from the stomach into the small intestine, prolonging the sensation of fullness after meals.

• Glucose-dependent insulin secretion and glucagon suppression: They stimulate insulin release in response to meals and reduce inappropriate glucagon secretion, helping to stabilise blood glucose levels. This is distinct from directly improving insulin sensitivity.

Semaglutide (Wegovy), administered as a once-weekly subcutaneous injection, has demonstrated significant weight loss outcomes in clinical trials. The STEP 1 trial (Wilding et al., NEJM 2021) showed average body weight reductions of approximately 15% over 68 weeks in adults without diabetes. Liraglutide (Saxenda), administered as a daily subcutaneous injection, has also shown clinically meaningful weight loss across the SCALE trial programme.

Tirzepatide (Mounjaro) targets both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. This dual mechanism has produced greater weight loss in clinical studies (SURMOUNT programme) compared with GLP-1 agonists alone, and tirzepatide received MHRA approval for weight management in the UK. Patients and prescribers should refer to the current MHRA/emc SmPC for Mounjaro for the precise licensed indication, dosing, and approval details.

These mechanisms represent a significant advance in understanding how hormonal pathways can be therapeutically targeted to address obesity as a chronic medical condition.

Who May Be Suitable for Hormone Weight Loss Treatment

Licensed indications generally include adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with a weight-related comorbidity, though NHS eligibility under NICE TAs is typically more restrictive and requires specialist oversight.

Hormone-based weight loss treatments are not appropriate for everyone. It is important to distinguish between three related but separate concepts:

1. Licensed indications (per MHRA/emc SmPCs): The clinical criteria under which a medicine is authorised for use in the UK.
2. NHS access criteria (per NICE Technology Appraisals): Often narrower than the licensed indication; these determine NHS funding eligibility.
3. Ethnicity-adjusted BMI thresholds for health risk (NICE PH46): Lower BMI thresholds at which health risks increase in South Asian, Black African, Black Caribbean, and some other ethnic groups. These inform clinical risk assessment but do not automatically confer eligibility for drug treatment.

Generally, licensed indications for GLP-1/GIP weight management medicines in the UK include adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity (exact thresholds vary by medicine — refer to individual SmPCs). NHS funding criteria under NICE TAs are typically more restrictive (see the NHS and NICE Guidelines section below).

These medicines are typically initiated and monitored by a specialist or GP with appropriate training, often within a structured weight management service. They are used alongside a reduced-calorie diet and increased physical activity.

Contraindications and cautions (per UK SmPCs):

• These medicines are not suitable for use during pregnancy or breastfeeding. Women of childbearing potential should use effective contraception. Semaglutide, for example, should be discontinued at least two months before a planned pregnancy — refer to the relevant SmPC for specific guidance.

• A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2) is listed as a contraindication in the US prescribing information for some GLP-1 medicines, based on animal data. This is not a formal contraindication in current UK SmPCs, where no established causal risk in humans has been confirmed; however, prescribers should exercise clinical judgement and refer to the relevant SmPC.

• A history of pancreatitis warrants caution. UK SmPCs advise that these medicines should be used with caution in patients with a history of pancreatitis, and should be discontinued if pancreatitis is suspected.

• These medicines are not currently licensed for use in children or adolescents for weight management, except where specifically stated in the SmPC.

Patients should have realistic expectations: evidence suggests that weight regain is common if medication is discontinued without sustained lifestyle changes. A thorough medical assessment is essential before starting treatment.

Risks, Side Effects and MHRA Safety Guidance

Common side effects include nausea, vomiting, and diarrhoea; serious risks include acute pancreatitis, gallbladder disease, and dehydration-related kidney injury — all suspected side effects should be reported via the MHRA Yellow Card scheme.

Experiencing these side effects? Our pharmacists can help you navigate them →

As with all prescription medicines, hormone-based weight loss treatments carry a risk of side effects, and patients should be fully informed before commencing therapy. The MHRA monitors the safety profile of these medicines through its Yellow Card pharmacovigilance scheme. Patients and healthcare professionals are encouraged to report any suspected side effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Common side effects associated with GLP-1 receptor agonists include:

• Nausea, vomiting, and diarrhoea (particularly during dose escalation)

• Constipation and abdominal discomfort

• Injection site reactions

• Fatigue and dizziness

• Small increases in resting heart rate (as observed in clinical studies and noted in SmPCs)

Most gastrointestinal side effects are dose-dependent and tend to improve over time. Gradual dose escalation is recommended to minimise these effects.

Important safety cautions:

• Dehydration and acute kidney injury (AKI): Persistent vomiting or diarrhoea can lead to dehydration, which may impair kidney function. Patients should maintain adequate fluid intake and seek medical advice if gastrointestinal symptoms are severe or prolonged.

• Hypoglycaemia: When used alongside insulin or sulfonylureas, there is an increased risk of hypoglycaemia. Dose adjustments of these concomitant medicines may be required.

• Diabetic retinopathy: In people with type 2 diabetes, rapid improvement in blood glucose control has been associated with worsening of diabetic retinopathy in some cases. Patients with pre-existing retinopathy should be monitored appropriately.

• Gallbladder disease: These medicines are associated with an increased risk of gallstones and cholecystitis. Patients should seek prompt medical attention if they develop right upper quadrant pain, fever, or jaundice.

More serious but less common risks include acute pancreatitis. Patients should seek urgent medical attention if they experience severe and persistent abdominal pain.

Suicidal ideation: The MHRA has reviewed a potential safety signal relating to suicidal ideation and self-harm with GLP-1 receptor agonist medicines (MHRA Drug Safety Update, 2023/2024). There is no confirmed causal link at this time, but monitoring is ongoing. Patients experiencing significant mood changes or thoughts of self-harm should contact their GP or seek urgent medical attention promptly.

Not sure if this is normal? Chat with one of our pharmacists →

Patients should seek urgent medical attention if they experience:

• Severe and persistent abdominal pain (possible pancreatitis)

• Symptoms of a serious allergic reaction, such as swelling of the face, lips, or throat, or difficulty breathing

• Symptoms of gallbladder problems: right upper quadrant pain, fever, or jaundice

• Significant mood changes or thoughts of self-harm

The MHRA advises that these medicines should only be used under medical supervision. Patients should not obtain them from unregulated online sources, where counterfeit products have been identified. Full safety information is available in the relevant MHRA/emc SmPCs.

NHS and NICE Guidelines on Weight Management Medicines

NICE technology appraisals recommend semaglutide (TA875), liraglutide (TA664), and tirzepatide for weight management within specialist services, subject to defined BMI thresholds, comorbidity criteria, and local commissioning decisions.

NICE has published specific technology appraisal guidance on the use of hormone-based weight loss medicines within the NHS. These guidelines reflect the clinical evidence base and help ensure equitable, cost-effective prescribing across England. NHS funding follows NICE TAs and is also subject to local commissioning decisions.

Key NICE guidance includes:

• TA875 — Semaglutide (Wegovy) for managing overweight and obesity: Recommended for adults with a BMI of 35 kg/m² or above and at least one weight-related comorbidity, or a BMI of 30–34.9 kg/m² in specific defined circumstances (for example, recent onset of type 2 diabetes or high cardiovascular risk), when used as part of a specialist weight management service. Treatment is recommended for a maximum of two years under NHS funding.

• TA664 — Liraglutide (Saxenda) for managing overweight and obesity: Recommended for adults with a BMI of 35 kg/m² or above, non-diabetic hyperglycaemia (prediabetes), and a high risk of cardiovascular disease, within a specialist weight management programme. Treatment is recommended for a maximum of two years.

• Tirzepatide (Mounjaro) for managing overweight and obesity: NICE issued a technology appraisal in 2024 recommending tirzepatide for weight management in adults meeting defined BMI and comorbidity thresholds, within a specialist service context. Patients and clinicians should refer to the current NICE TA for the precise eligibility criteria, service requirements, and any specified treatment duration.

It is important to note that NHS availability of these medicines remains subject to local commissioning decisions and specialist service capacity. Not all patients who meet NICE criteria will have immediate access through the NHS, and waiting times for specialist weight management services can be considerable in some areas.

Patients are encouraged to discuss their eligibility with their GP, who can refer them to appropriate services. Private prescribing is available but carries its own considerations around cost, monitoring, and continuity of care. NICE emphasises that pharmacological treatment should always be part of a multicomponent approach that includes dietary, physical activity, and behavioural support.

Alternatives and Wider Support for Weight Loss in the UK

NHS alternatives include the Digital Weight Management Programme, Tier 2–4 weight management services, orlistat, and bariatric surgery for severe obesity, with psychological support recommended as a core component of any approach.

Hormone-based weight loss medications represent one component of a broader toolkit for managing obesity in the UK. For many individuals, lifestyle interventions remain the foundation of treatment and can achieve meaningful, sustained weight loss when properly supported.

NHS-supported options include:

• NHS Digital Weight Management Programme: A free, online behavioural programme for adults with obesity and a related condition such as type 2 diabetes or hypertension. Further information is available on the NHS website.

• Tier 2 and Tier 3 weight management services: Structured community and specialist programmes offering dietary advice, physical activity support, and psychological input.

• Tier 4 (bariatric surgery): For individuals with severe obesity (BMI ≥ 40 kg/m², or ≥ 35 kg/m² with significant comorbidities), bariatric surgery may be considered when other interventions have not achieved adequate weight loss and the individual is fit for surgery. NICE guidance also supports consideration of metabolic surgery at lower BMI thresholds in people with type 2 diabetes — refer to NICE CG189 (or its successor guidance) for details.

• Orlistat (Alli/Xenical): A non-hormonal prescription medicine that reduces fat absorption in the gut. It is available on the NHS and is recommended by NICE as an option for eligible patients within a multicomponent weight management programme. NHS medicines information for orlistat is available on the NHS website.

Psychological support is an often-overlooked but vital element of weight management. Cognitive behavioural therapy (CBT) and motivational interviewing can help address the emotional and behavioural drivers of overeating. Patients experiencing disordered eating patterns should be referred to appropriate mental health services.

Ultimately, sustainable weight management requires a personalised, compassionate approach. Patients are encouraged to speak openly with their GP about all available options — including the potential role of hormone-based treatments — to find a plan that is safe, evidence-based, and suited to their individual health needs and circumstances.

Frequently Asked Questions